WebDoxorubicin is a type of chemotherapy drug called an anthracycline. It works by blocking an enzyme called topoisomerase 2 that cancer cells need in order to divide and grow. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated … WebOct 19, 2024 · A single-center, phase II, single-arm, feasibility study to evaluate PLD (Caelyx®) as an adjuvant chemotherapy regimen in patients with early-stage luminal B breast cancer. The primary endpoint will be to evaluate the feasibility of adjuvant PLD (Caelyx®) for each individual subject. The regimen will be considered feasible if that …
Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort …
WebThe side effects with Caelyx depend on the type of cancer being treated. The most common side effect seen in all types of cancer (in more than 1 patient in 10) is nausea (feeling sick). Other very common side effects include palmar-plantar erythrodysaesthesia syndrome … WebIn 254 breast cancer patients treated with CAELYX® at a dose of 50 mg/m2 body surface, every 4 weeks, 42 patients (17%) reported Grade III PPE, and no cases of Grade IV PPE were reported. Discontinuations due to PPE were infrequent (17 patients, 7%). In 512 ovarian cancer patients treated with CAELYX® at a dose of 50 mg/m2 body surface, 100 red flushed skin on arms
Chemotherapy Protocol GYNAECOLOGICAL CANCER …
WebThe initial approved indication for Caelyx was the treatment of Kaposi’s sarcoma (KS) in patients with human immunodeficiency syndrome (AIDS). Caelyx may be used as first-line systemic ... Caelyx consists of a liposomal formulation of doxorubicin HCl encapsulated in a delivery system of long circulating liposomes (Stealth® or sterically ... WebCAELYX was significantly less myelosuppressive, only 3 (6%) patients had grade 3 and 4 neutropenia, versus 33 (77%) on doxorubicin; febrile neutropenia occurred in 7 (16%) patients given doxorubicin, but only 1 (2%) given CAELYX. 37 (86%) patients on doxorubicin had grade 2-3 alopecia, but only 3 (6%) on CAELYX, and the major toxicity … WebFeb 17, 2024 · Fourth-quarter U.S. GAAP earnings per share (EPS) of $0.47 and adjusted EPS of $1.04. Full-year revenue of $12.8 billion increased 10% on a reported basis, 7% on a constant currency basis and 5% on an operational basis. Full-year U.S. GAAP EPS of $2.53 and adjusted EPS of $3.61. Baxter's acquisition of Hillrom positions company to … red flushed palms